An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials

Melissa K Andrew,1 Sean Matthews,2 Joon Hyung Kim,3 Megan E Riley,3 Desmond Curran4 1Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Halifax, Nova Scotia, Canada; 2Freelance C/O GSK, Wavre, Belgium; 3GSK, Rockville, MD, USA; 4GSK, Wavre, BelgiumCorrespondence: Melissa...

Full description

Bibliographic Details
Main Authors: Andrew MK, Matthews S, Kim JH, Riley ME, Curran D
Format: Article
Language:English
Published: Dove Medical Press 2022-08-01
Series:Clinical Interventions in Aging
Subjects:
Online Access:https://www.dovepress.com/an-easy-to-implement-clinical-trial-frailty-index-based-on-accumulatio-peer-reviewed-fulltext-article-CIA
_version_ 1811340077676101632
author Andrew MK
Matthews S
Kim JH
Riley ME
Curran D
author_facet Andrew MK
Matthews S
Kim JH
Riley ME
Curran D
author_sort Andrew MK
collection DOAJ
description Melissa K Andrew,1 Sean Matthews,2 Joon Hyung Kim,3 Megan E Riley,3 Desmond Curran4 1Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Halifax, Nova Scotia, Canada; 2Freelance C/O GSK, Wavre, Belgium; 3GSK, Rockville, MD, USA; 4GSK, Wavre, BelgiumCorrespondence: Melissa K Andrew, C/O Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Veterans Memorial Building, 5955 Veterans Memorial Drive, Halifax, NS, Canada, Tel +1 902 473-4995, Fax +1 902 473-7133, Email mandrew@dal.caPurpose: Despite being among those most in need of protection, frail older adults are often not well represented in clinical trials. Although frailty likely influences responses to treatments and vaccines, frailty may not be explicitly considered in trials even when frail participants are enrolled due to the perception that frailty is difficult to measure effectively and efficiently without adding to participant or data collection burden. We developed an easy-to-implement frailty index, the Clinical Trial-Frailty Index (CT-FI), based on baseline medical history and standard patient-reported outcomes using data from clinical trials of recombinant Zoster vaccine (the ZOE-50 and ZOE-70 studies). Our objective was to demonstrate that the CT-FI is a robust measure that may be used retrospectively or prospectively in clinical trials where sufficient patient data have been collected.Methods: The CT-FI was based on baseline medical history and Quality of Life questionnaires (SF-36 and EQ-5D). Items meeting criteria for inclusion were scored from 0 to 1, then summed for each participant and divided by the total number of deficits considered. Validation analyses included descriptive verification of distribution and age- and sex-associations in relation to usual patterns of the frailty index, regressions in relation to outcomes hypothesized to be related to frailty, and resampling methods within the index.Results: The CT-FI distribution was well represented by a gamma distribution with a range of 0– 0.70. Deficit accumulation increased with chronological age and was higher for females. Multivariate Cox regression survival analysis showed that the CT-FI, age, and sex were significant predictors of mortality. Jackknife and Bootstrap resampling methods highlighted the robustness of the CT-FI, which was not sensitive to inclusion/exclusion of specific individual or groups of variables.Conclusion: We have developed a reliable, robust and easy-to-implement CT-FI with potential retrospective or prospective application in other clinical trials.Keywords: frailty, frail elderly, older adults, herpes zoster, quality of life, vaccine, clinical trial
first_indexed 2024-04-13T18:36:08Z
format Article
id doaj.art-5c38d82c4b7e479d81994256dd28b71e
institution Directory Open Access Journal
issn 1178-1998
language English
last_indexed 2024-04-13T18:36:08Z
publishDate 2022-08-01
publisher Dove Medical Press
record_format Article
series Clinical Interventions in Aging
spelling doaj.art-5c38d82c4b7e479d81994256dd28b71e2022-12-22T02:34:52ZengDove Medical PressClinical Interventions in Aging1178-19982022-08-01Volume 171261127477504An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical TrialsAndrew MKMatthews SKim JHRiley MECurran DMelissa K Andrew,1 Sean Matthews,2 Joon Hyung Kim,3 Megan E Riley,3 Desmond Curran4 1Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Halifax, Nova Scotia, Canada; 2Freelance C/O GSK, Wavre, Belgium; 3GSK, Rockville, MD, USA; 4GSK, Wavre, BelgiumCorrespondence: Melissa K Andrew, C/O Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Veterans Memorial Building, 5955 Veterans Memorial Drive, Halifax, NS, Canada, Tel +1 902 473-4995, Fax +1 902 473-7133, Email mandrew@dal.caPurpose: Despite being among those most in need of protection, frail older adults are often not well represented in clinical trials. Although frailty likely influences responses to treatments and vaccines, frailty may not be explicitly considered in trials even when frail participants are enrolled due to the perception that frailty is difficult to measure effectively and efficiently without adding to participant or data collection burden. We developed an easy-to-implement frailty index, the Clinical Trial-Frailty Index (CT-FI), based on baseline medical history and standard patient-reported outcomes using data from clinical trials of recombinant Zoster vaccine (the ZOE-50 and ZOE-70 studies). Our objective was to demonstrate that the CT-FI is a robust measure that may be used retrospectively or prospectively in clinical trials where sufficient patient data have been collected.Methods: The CT-FI was based on baseline medical history and Quality of Life questionnaires (SF-36 and EQ-5D). Items meeting criteria for inclusion were scored from 0 to 1, then summed for each participant and divided by the total number of deficits considered. Validation analyses included descriptive verification of distribution and age- and sex-associations in relation to usual patterns of the frailty index, regressions in relation to outcomes hypothesized to be related to frailty, and resampling methods within the index.Results: The CT-FI distribution was well represented by a gamma distribution with a range of 0– 0.70. Deficit accumulation increased with chronological age and was higher for females. Multivariate Cox regression survival analysis showed that the CT-FI, age, and sex were significant predictors of mortality. Jackknife and Bootstrap resampling methods highlighted the robustness of the CT-FI, which was not sensitive to inclusion/exclusion of specific individual or groups of variables.Conclusion: We have developed a reliable, robust and easy-to-implement CT-FI with potential retrospective or prospective application in other clinical trials.Keywords: frailty, frail elderly, older adults, herpes zoster, quality of life, vaccine, clinical trialhttps://www.dovepress.com/an-easy-to-implement-clinical-trial-frailty-index-based-on-accumulatio-peer-reviewed-fulltext-article-CIAfrailtyfrail elderlyolder adultsherpes zosterquality of lifevaccineclinical trial
spellingShingle Andrew MK
Matthews S
Kim JH
Riley ME
Curran D
An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials
Clinical Interventions in Aging
frailty
frail elderly
older adults
herpes zoster
quality of life
vaccine
clinical trial
title An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials
title_full An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials
title_fullStr An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials
title_full_unstemmed An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials
title_short An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials
title_sort easy to implement clinical trial frailty index based on accumulation of deficits validation in zoster vaccine clinical trials
topic frailty
frail elderly
older adults
herpes zoster
quality of life
vaccine
clinical trial
url https://www.dovepress.com/an-easy-to-implement-clinical-trial-frailty-index-based-on-accumulatio-peer-reviewed-fulltext-article-CIA
work_keys_str_mv AT andrewmk aneasytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT matthewss aneasytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT kimjh aneasytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT rileyme aneasytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT currand aneasytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT andrewmk easytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT matthewss easytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT kimjh easytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT rileyme easytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials
AT currand easytoimplementclinicaltrialfrailtyindexbasedonaccumulationofdeficitsvalidationinzostervaccineclinicaltrials